Similar articles

• Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia.

  Buckner CD, Clift RA, Appelbaum FR, Storb R, Petersen FB, Sanders JE, Thomas ED, Hansen JA. Buckner CD, et al. Bone Marrow Transplant. 1991;7 Suppl 2:6-8. Bone Marrow Transplant. 1991. PMID: 1878723 Clinical Trial. No abstract available.
• Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.

  Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M. Carlens S, et al. Clin Transplant. 1998 Apr;12(2):84-92. Clin Transplant. 1998. PMID: 9575394
• Bone marrow transplantation for the treatment of leukaemia-results of the Munich Cooperative Group.

  Kolb HJ, Bender-Götze C, Haas RJ, Holler E, Thierfelder S, Wilmanns W. Kolb HJ, et al. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(3-4):397-402. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989. PMID: 2480280 Clinical Trial.
• [The allograft in chronic myeloid leukemia].

  Arcese W, Mauro FR, Screnci M, Iori AP, Papa G, Mandelli F. Arcese W, et al. Haematologica. 1989 Oct;74(5 Suppl):443-59. Haematologica. 1989. PMID: 2512228 Review. Italian. No abstract available.
• Effects of treatment regimens on post marrow transplant relapse.

  Buckner CD, Clift RA, Appelbaum FR, Storb R, Fefer A, Petersen FB, Sanders JE, Sullivan K, Thomas ED, Hansen JA. Buckner CD, et al. Semin Hematol. 1991 Jul;28(3 Suppl 4):32-4. Semin Hematol. 1991. PMID: 1780749 Review. No abstract available.